BXCL501

DRUG5 trials

Sponsors

BioXcel Therapeutics Inc

Conditions

AgitationAgitation,PsychomotorBipolar I DisorderBipolar II DisorderDeliriumDementiaSchizoaffective DisorderSchizophrenia

Phase 2

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

TerminatedNCT05276830

BioXcel Therapeutics IncAgitation, Dementia

Start: 2022-02-08End: 2022-04-01Updated: 2026-08-11

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

WithdrawnNCT05313386

BioXcel Therapeutics IncAgitation, Delirium

Start: 2021-02-23End: 2022-02-21Updated: 2026-08-11

Phase 3

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

CompletedNCT05271552

BioXcel Therapeutics IncAgitation, Dementia

Start: 2022-04-27End: 2023-04-21Updated: 2026-08-11

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

CompletedNCT05658510

BioXcel Therapeutics IncAgitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder +3

Start: 2022-11-21End: 2025-08-15Updated: 2026-08-07

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

TerminatedNCT05665088

BioXcel Therapeutics IncAgitation, Dementia

Start: 2022-12-14End: 2023-09-11Updated: 2023-12-11